Global Spinal Muscular Atrophy Treatment Market 2019-2023

脊髄性筋萎縮症治療の世界市場2019-2023

◆タイトル:Global Spinal Muscular Atrophy Treatment Market 2019-2023
◆商品コード:IRTNTR30198
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月21日
◆ページ数:99
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

新しく革新的療法の開発の増加に伴い、脊髄性筋萎縮症治療に対する需要が高まっています。市場では、脊髄性筋萎縮症治療に対する新しい革新的療法の開発が増えています。
例えば、1型脊髄性筋萎縮症に対する新しい二つの革新的治療法が、進行中の臨床試験において非常に有効であることが証明されています。
最初の治療では、失われたSMN1遺伝子を新しい遺伝子で置換するためにDNA担持ウイルスを使用しました。
すでにFDAによって承認されている2番目の治療法は、ヌシネルセン(スピンラザ)と呼ばれています。

主な分析対象企業は、Biogenなどです。

当調査レポートでは、脊髄性筋萎縮症治療の世界市場について調査・分析し、市場概要、市場環境、脊髄性筋萎縮症治療市場規模、種類別(2型、3型、1型、4型)分析、治療型別分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・脊髄性筋萎縮症治療の世界市場概要
・脊髄性筋萎縮症治療の世界市場環境
・脊髄性筋萎縮症治療の世界市場動向
・脊髄性筋萎縮症治療の世界市場規模
・脊髄性筋萎縮症治療の世界市場:業界構造分析
・脊髄性筋萎縮症治療の世界市場:種類別(2型、3型、1型、4型)
・脊髄性筋萎縮症治療の世界市場:治療型別
・脊髄性筋萎縮症治療の世界市場:地域別市場規模・分析
・脊髄性筋萎縮症治療の北米市場規模・予測
・脊髄性筋萎縮症治療のヨーロッパ・中東・アフリカ市場規模・予測
・脊髄性筋萎縮症治療のアジア太平洋市場規模・予測
・脊髄性筋萎縮症治療の主要国分析
・脊髄性筋萎縮症治療の世界市場:意思決定フレームワーク
・脊髄性筋萎縮症治療の世界市場:成長要因、課題
・脊髄性筋萎縮症治療の世界市場:競争環境
・脊髄性筋萎縮症治療の世界市場:関連企業情報(ベンダー分析)

98 pages, November 2018
About this market
With the increase in development of new innovative therapies, there is a growing demand for spinal muscular atrophy treatment. The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials. The first therapy employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh copy of the gene. The second therapy, which has already been approved by the FDA, is called nusinersen (SPINRAZA). It promotes the production of the nerve protein by SMN2. These two therapies have improved the motor function in babies. AveXis in 2018, entered into a licensing agreement with Genethon for the in vivo gene therapy delivery of AAV9 vector into the CNS for the treatment of spinal muscular atrophy. Technavio’s analysts have predicted that the spinal muscular atrophy treatment market will register a CAGR of almost 23% by 2023.
Market Overview
Rising number of initiatives being taken by organizations to provide patient care
Several organizations are taking initiatives to provide the best care to patients suffering from spinal muscular atrophy, and some organizations such as Cure SMA are offering care packages and family support staff to newly diagnosed patients.
Low adoption of spinal muscular atrophy treatment
One of the major challenges faced in the market is low adoption of spinal muscular atrophy drug therapy as patients have a higher propensity towards other approaches, such as physiotherapy, nutritional support, respiratory care, and enablement strategies.
For the detailed list of factors that will drive and challenge the growth of the spinal muscular atrophy treatment market during the 2019-2023 period, view our report.
Competitive Landscape
The market appears to be highly concentrated and with the presence of Biogen, the market is expected to grow less concentrated with the emergence of new players during the forecast period. Factors such as increase in development of new innovative therapies and rising number of initiatives being taken by organizations to provide patient care, will provide considerable growth opportunities to spinal muscular atrophy treatment companies. Biogen is the major company covered in this report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
• PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Type 2 – Market size and forecast 2018-2023
• Type 3 – Market size and forecast 2018-2023
• Type 1 – Market size and forecast 2018-2023
• Type 4 – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TREATMENT
• Segmentation by treatment
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Rising awareness of treatment and diagnosis of spinal muscular atrophy
• Development of new innovative therapies for treatment
• Advances in diagnostic techniques
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen
PART 16: APPENDIX
• Research methodology
• List of abbreviations
PART 17: EXPLORE TECHNAVIO

Exhibit 01: Global CNS disorder drugs market
Exhibit 02: Segments of global cns disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline agents for spinal muscular atrophy
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Type 2 – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Type 2 – Year-over-year growth 2019-2023 (%)
Exhibit 22: Type 3 – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Type 3 – Year-over-year growth 2019-2023 (%)
Exhibit 24: Type 1 – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Type 1 – Year-over-year growth 2019-2023 (%)
Exhibit 26: Type 4 – Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Type 4 – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 34: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 36: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Biogen – Vendor overview
Exhibit 47: Biogen – Business segments
Exhibit 48: Biogen – Organizational developments
Exhibit 49: Biogen – Geographic focus
Exhibit 50: Biogen – Key offerings



【掲載企業】

Biogen

★調査レポート[脊髄性筋萎縮症治療の世界市場2019-2023] (Global Spinal Muscular Atrophy Treatment Market 2019-2023 / IRTNTR30198)販売に関する免責事項
[脊髄性筋萎縮症治療の世界市場2019-2023] (Global Spinal Muscular Atrophy Treatment Market 2019-2023 / IRTNTR30198)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆